Alana Fakhri
Alana Fakhri has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Adam Valkovic
Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
2 shared publications Claire Storey
Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research , Parkville (Z.M., C.S., A.V., M.S., J.F.P., S.J.O., O.M.S., J.R.W, S.F., S.A.B.)
2 shared publications- Daniel V. Brown
The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
2 shared publications - James R. Whittle
Cancer Division, Walter and Eliza Hall Institute , Parkville
2 shared publications - Jasmine F. Pignatelli
Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research , Parkville (Z.M., C.S., A.V., M.S., J.F.P., S.J.O., O.M.S., J.R.W, S.F., S.A.B.)
2 shared publications - Katharine Jann Drummond
Department of Neurosurgery, Royal Melbourne Hospital, Melbourne, Australia
2 shared publications
Latest Publications
- Open Access
- 22 November 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Patient-derived organoids and neurospheres recapitulate salient features of primary tumor heterogeneity
Background: The intra- and inter-tumoral heterogeneity of glioblastoma (GBM) represents a significant therapeutic challenge and barrier to the generation of reliable and accurate models for in vitro studies. Three-dimensional models, such as patient-derived neurospheres (PDN) and organoids (PDO), recapitulate complex cellular states. However, the direct comparison of models derived in parallel from the same primary tumor tissue has never been performed. The aim of this study was to determine the tumor cell composition of PDN and PDO models relative to matched primary GBM tissue. Methods: Four GBM surgical samples were used to establish matched PDO and PDN models, which were genomically verified using single nucleotide polymorphism array. DNA methylation, histology, and transcriptome were examined for intra-tumoral heterogeneity correlating with the matched GBM tissue. PDN lines were used to investigate the tumor cell composition response to temozolomide chemotherapy over time, maximizing their utility. Results: We find that both patient-derived models recapitulate the genomic, epigenomic, and tumor cell heterogeneity of the primary tissue at similar capacity. Furthermore, single-nuclei RNA sequencing revealed a subset of organoids containing small numbers of non-malignant cells from neuron and immune cell lineages. Harnessing the intra-tumoral heterogeneity of PDN models, we reveal the impact of temozolomide chemotherapy on individual cell states, altering composition of tumors over time in response to treatment. Conclusions: Our data confirms that both PDN and PDO patient-derived models recapitulate patient intra-tumoral heterogeneity providing a platform for tumor cell state refined therapeutic studies.
- 22 November 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Open AccessPatient-derived organoids and neurospheres recapitulate salient features of primary tumor heterogeneity
Background: The intra- and inter-tumoral heterogeneity of glioblastoma (GBM) represents a significant therapeutic challenge and barrier to the generation of reliable and accurate models for in vitro studies. Three-dimensional models, such as patient-derived neurospheres (PDN) and organoids (PDO), recapitulate complex cellular states. However, the direct comparison of models derived in parallel from the same primary tumor tissue has never been performed. The aim of this study was to determine the tumor cell composition of PDN and PDO models relative to matched primary GBM tissue. Methods: Four GBM surgical samples were used to establish matched PDO and PDN models, which were genomically verified using single nucleotide polymorphism array. DNA methylation, histology, and transcriptome were examined for intra-tumoral heterogeneity correlating with the matched GBM tissue. PDN lines were used to investigate the tumor cell composition response to temozolomide chemotherapy over time, maximizing their utility. Results: We find that both patient-derived models recapitulate the genomic, epigenomic, and tumor cell heterogeneity of the primary tissue at similar capacity. Furthermore, single-nuclei RNA sequencing revealed a subset of organoids containing small numbers of non-malignant cells from neuron and immune cell lineages. Harnessing the intra-tumoral heterogeneity of PDN models, we reveal the impact of temozolomide chemotherapy on individual cell states, altering composition of tumors over time in response to treatment. Conclusions: Our data confirms that both PDN and PDO patient-derived models recapitulate patient intra-tumoral heterogeneity providing a platform for tumor cell state refined therapeutic studies.
- Open Access
Three-dimensional patient-derived models of glioblastoma retain intra-tumoral heterogeneity
The intra- and inter-tumoral heterogeneity of glioblastoma represents a significant therapeutic challenge, as well as difficulty in generating reliable models for in vitro studies. Historical 2D adherent cell lines do not recapitulate this complexity, whereas both patient-derived neurospheres (PDN) and organoids (PDO) demonstrate intra-tumoral heterogeneity. Here, we quantify the tumor cell composition from matched models established from the same primary tumor using a series of multi-omic interrogations. We find that both patient-derived models recapitulate the genomic, epigenomic and tumor cell heterogeneity of the primary tissue. Furthermore, single-nuclei RNA sequencing revealed a subset of organoids containing small numbers of non-malignant cells from neuron and immune cell lineages. Harnessing the intra-tumoral heterogeneity of PDN models, we reveal the impact of temozolomide chemotherapy on individual cell states, altering composition of tumors over time in response to treatment. Our data confirms that both patient-derived models recapitulate patient intra-tumoral heterogeneity providing a platform for tumor cell state refined therapeutic studies. Key Points: Generation of matched patient-derived neurosphere and organoid models from resected GBM tissue Neurosphere models exhibit greater proliferative signatures Both patient-derived models recapitulate genomic and epigenomic features of the primary tissue Single-nuclei RNA sequencing reveals both models recapitulate intra-tumoral heterogeneity of the primary tissue Neurosphere models enable interrogation of therapeutic responses in the context of heterogeneity Importance of study: Patient derived models can be powerful tools when they faithfully recapitulate the tumor tissue from which they are derived. In glioblastoma, patient derived neurospheres (PDN) and organoids (PDO) have both been used in studies, however the differences between these models and the recapitulation of patient heterogeneity remain to be fully characterized. To address this, we performed multi-omic profiling of PDN and PDO models generated from the same tumor tissue. We find that that across a range of data modalities, both model systems exhibit a high level of resemblance to tissue, and critically, maintain heterogeneity and tumor cell composition. The importance of modeling heterogeneity was demonstrated in PDN models, where temozolomide treatment specifically alters the abundance of MES-like and AC-like tumor cells. Our findings demonstrate that neurosphere and organoid models effectively preserve cellular heterogeneity, genomic alterations, methylation signatures and transcriptomic features, both highly suitable to model glioblastoma’s complex cellular landscape.
Open AccessThree-dimensional patient-derived models of glioblastoma retain intra-tumoral heterogeneity
The intra- and inter-tumoral heterogeneity of glioblastoma represents a significant therapeutic challenge, as well as difficulty in generating reliable models for in vitro studies. Historical 2D adherent cell lines do not recapitulate this complexity, whereas both patient-derived neurospheres (PDN) and organoids (PDO) demonstrate intra-tumoral heterogeneity. Here, we quantify the tumor cell composition from matched models established from the same primary tumor using a series of multi-omic interrogations. We find that both patient-derived models recapitulate the genomic, epigenomic and tumor cell heterogeneity of the primary tissue. Furthermore, single-nuclei RNA sequencing revealed a subset of organoids containing small numbers of non-malignant cells from neuron and immune cell lineages. Harnessing the intra-tumoral heterogeneity of PDN models, we reveal the impact of temozolomide chemotherapy on individual cell states, altering composition of tumors over time in response to treatment. Our data confirms that both patient-derived models recapitulate patient intra-tumoral heterogeneity providing a platform for tumor cell state refined therapeutic studies. Key Points: Generation of matched patient-derived neurosphere and organoid models from resected GBM tissue Neurosphere models exhibit greater proliferative signatures Both patient-derived models recapitulate genomic and epigenomic features of the primary tissue Single-nuclei RNA sequencing reveals both models recapitulate intra-tumoral heterogeneity of the primary tissue Neurosphere models enable interrogation of therapeutic responses in the context of heterogeneity Importance of study: Patient derived models can be powerful tools when they faithfully recapitulate the tumor tissue from which they are derived. In glioblastoma, patient derived neurospheres (PDN) and organoids (PDO) have both been used in studies, however the differences between these models and the recapitulation of patient heterogeneity remain to be fully characterized. To address this, we performed multi-omic profiling of PDN and PDO models generated from the same tumor tissue. We find that that across a range of data modalities, both model systems exhibit a high level of resemblance to tissue, and critically, maintain heterogeneity and tumor cell composition. The importance of modeling heterogeneity was demonstrated in PDN models, where temozolomide treatment specifically alters the abundance of MES-like and AC-like tumor cells. Our findings demonstrate that neurosphere and organoid models effectively preserve cellular heterogeneity, genomic alterations, methylation signatures and transcriptomic features, both highly suitable to model glioblastoma’s complex cellular landscape.